InMedica: Slovenian Device Incubator Looks To Fill Infrastructure Gap
One of the major challenges faced by a European medtech start-up community that is already arguably undersized has been a lack of infrastructure. A group of medical device executives are trying to address that problem through the launch of an incubator, InMedica, built upon a network of support services that is integrally connected to the incubator, in effect forming its own medical device cluster in the unlikely setting of Slovenia, a country of two million people in south central Europe.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.